|
朱芳.增强型体外反博对Ⅰ型心肌梗死患者冠脉介入术后睡眠障碍及炎症因子水平有改善作用[J].内科急危重症杂志,2026,32(3):240-244
|
| DOI：10.11768/nkjwzzzz20260307 |
| 中文关键词: Ⅰ型心肌梗死 经皮冠状动脉介入术 增强型体外反博 睡眠障碍 炎症因子 |
| 英文关键词:Type Ⅰ myocardial infarction Percutaneous coronary intervention Enhanced external counterpulsation Sleep disorders Inflammatory marker |
| 基金项目:嘉定区卫健委课题 （2022- KY- 04） |
|
| 摘要点击次数: 114 |
| 全文下载次数: 78 |
| 中文摘要: |
| 摘要 目的：探究增强型体外反博对急性ST段抬高型心肌梗死（STEMI）患者经皮冠状动脉介入治疗手术（PCI）后睡眠障碍及炎症因子的影响。方法：选取确诊心肌梗死患者160例，随机分为对照组和观察组，各80例，2组患者行PCI术后，对照组接受常规药物治疗和安全知识教育，观察组在对照组治疗基础上联合增强型体外反搏(EECP)治疗方案。比较观察组和对照组患者治疗前、后的血清白细胞介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）水平，并根据匹茨堡睡眠质量指数（PSQI）、汉密尔顿抑郁量表（HAMD）、健康状况量表（SF-36）评分对患者的睡眠质量和生活水平进行评估，比较2组治疗后的再次住院次数以及临床疗效。结果：治疗后2组患者的血清IL-6、TNF-α水平以及PSQI指数、HAMD评分明显下降，SF-36评分显著升高（P均＜0.05），且观察组的改善程度较对照组显著（P均＜0.05）。观察组治疗有效率显著高于对照组（91.25% vs 61.25%，P＜0.05）；2组再次入院病例数无统计学差异（P＞0.05）。结论：增强型体外反博治疗能降低Ⅰ型心肌梗死患者PCI术后血清炎症因子水平，提高患者睡眠质量，降低焦虑情绪，对控制病情的反复发作效果显著。 |
| 英文摘要: |
| Abstrac Objective: To investigate the effects of enhanced external counterpulsation(EECP) on sleep disturbances and inflammatory markers in patients with acute ST-segment elevation myocardial infarction (STEMI) following percutaneous coronary intervention (PCI). Methods: A total of 160 patients diagnosed with STEMI were selected and randomly divided into a control group and an observation group, with 80 cases in each group. Following PCI, patients in both groups received standard medical treatment and safety education. The observation group received EECP therapy in addition to the standard treatment regimen. Serum levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) were compared between the observation and control groups before and after treatment. Sleep quality and quality of life were assessed using the Pittsburgh Sleep Quality Index (PSQI), the Hamilton Depression Rating Scale (HAMD), and the Health Status Questionnaire (SF-36). The number of readmissions and clinical efficacy were compared between the two groups following treatment. Results: After treatment, serum IL-6 and TNF-α levels, as well as PSQI scores and HAMD scores, decreased significantly in both groups, while SF-36 scores increased significantly (all P< 0.05); moreover, the degree of improvement was significantly greater in the observation group than in the control group (all P< 0.05). The treatment efficacy rate in the observation group was significantly higher than that in the control group (91.25% vs 61.25%, P< 0.05); there was no statistically significant difference in the number of readmissions between the two groups (P> 0.05). Conclusion: EECP therapy reduces serum inflammatory marker levels in patients with type I myocardial infarction following PCI, improves sleep quality, reduces anxiety, and is highly effective in preventing recurrence of the condition. |
|
